All in for ALL Mitigating VOD Risk in Patients Being Treated for R/R ALL

July 15, 2022
Michigan State University
 
Historically, the prognosis of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) has been poor with median overall survival (OS) of only 6 months and cure rates of less than 10%, even with intensive salvage chemotherapy and hematopoietic stem cell transplant (HSCT). (Samra, 2020) However, with the advent of new and revolutionary therapies, including a CD22-directed antibody drug conjugate inotuzumab ozogamicin (InO), outcomes for patients have improved exponentially. (Samra, 2020) Yet while InO is highly active, it has a unique hepatotoxicity profile, including a higher risk of veno-occlusive disease (VOD) in recipients of HSCT. (Kebriaei, 2018) For this reason, effective patient management must include evaluation and management of the important AEs associated with this therapy, with a focus on diagnosis, prevention, monitoring, and management of VOD. (Kebriaei, 2018)
To effectively translate expert guidance to practice and build clinician confidence in optimizing therapeutic benefit through management of AEs, clinicians benefit from peer-to-peer exchanges to model best practices and discuss practical strategies to achieve goals. Fortunately, with education clinicians’ attitudes, knowledge, competence and behavior can change. To enable clinicians to deliver a personalized approach to care University of Chicago and ACHL are proposing to create an opportunity for small group learning among community oncologist via live visiting professorship programs (VPPs).
 
The VPP is education delivered via small group live settings (faculty will be virtual) in hospitals and community cancer centers throughout the country. The small group setting of the VPP affords clinicians a forum to interact with their colleagues, share real world experiences, have collaborative discussion, and address key challenges with the current environment, while fostering a safe environment for social exchange.
 
The goal of this education is to build clinical confidence in the multidisciplinary treatment teams by supporting peer-to-peer learning. These small group meetings foster direct interaction between hematologists in a supportive, non-threatening atmosphere thereby encouraging discussion of and reflection on, clinical concerns, barriers and opportunities for improved practice, consultations, and more. For clinicians who may reside in non-urban settings, it provides a great opportunity for networking and outreach to colleagues outside of their network.
 

Educational Partner: Academy for Continued Healthcare Learning (ACHL)

Commercial Support: Support for this activity has been provided through an educational grant from Pfizer.

Target Audience

This activity is intended for hematologists/oncologists, oncology nurses, and others on the multidisciplinary healthcare team who are involved in the care of patients with R/R ALL.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Create optimal relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treatment plans in terms of treatment selection, sequencing, and dosing while incorporating patient point-of-care (inpatient vs outpatient);
  • Incorporate strategies and tools to mitigate and manage veno-occlusive disease (VOD) risk in patients with R/R ALL proceeding to hematopoietic stem cell transplantation (HSCT);
  • Outline tactics to facilitate interdisciplinary communication and decision making.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
ACHL
CME Coordinator Contact Phone: 
877-444-8435 ext 160
AttachmentSize
PDF icon ALL Flyer.pdf617.93 KB
Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Event starts: 
07/15/2022 - 12:00pm
Event ends: 
07/15/2022 - 1:00pm
Activity opens: 
07/15/2022
Activity expires: 
10/15/2022
Add to calendar: 
Webinar
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
 
Questions?
Contact ACHL via their website.
 
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org.


The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.

CHAIRS
  Partow Kebriaei, MD
  The University of Texas
  MD Anderson Cancer Center
  Houston, TX
 

  Richard Larson, MD
  The University of Chicago
  Chicago, IL
 
 
 
FACULTY
  Nelson Chao, MD, MBA
  Duke University Medical Center
  Durham, NC
 
 

  Marlise Luskin, MD, MSCE
  Dana Farber Cancer Institute
  Boston, MA
 
 

  Hongtao Liu, MD, PhD
  The University of Chicago
  Chicago, IL
 
 

  Kris Mahadeo, MD MPH
  The University of Texas
  MD Anderson Cancer Center
  Houston, TX
 

 

Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
 
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
REGISTRATION: For additional information, click the button below or visit the ACHL website!
 
Please login or create an account to proceed.